<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00968045</url>
  </required_header>
  <id_info>
    <org_study_id>Fibro 01/07</org_study_id>
    <secondary_id>EudraCT-nr:2007-007157-31</secondary_id>
    <nct_id>NCT00968045</nct_id>
  </id_info>
  <brief_title>Fibrinogen and Bleeding After Cardiac Surgery</brief_title>
  <acronym>Fibro-3</acronym>
  <official_title>Fibrinogen and Bleeding After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that prophylactic fibrinogen infusion reduces postoperative bleeding
      and transfusion requirements after coronary artery bypass surgery (CABG) in patients with
      endogenous fibrinogen levels in the lower normal range. 60 patients will be included in a
      prospective, randomized double-blind placebo-controlled single center study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety of prophylactic fibrinogen infusion in patients with fibrinogen levels in the lower normal range undergoing cardiac surgery</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood loss first 12 postoperative hours</measure>
    <time_frame>12h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusions</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of coagulation, fibrinolysis and platelet function</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmcoeconomic analysis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Complications</condition>
  <condition>Bleeding</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 ml infusion of saline is given during 15 minutes after anesthesia induction before start of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fibrinogen 2g in 100 ml sterile water given during 15 minutes after anestesiainduction before surgery start</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrinogen</intervention_name>
    <description>Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Study drug</arm_group_label>
    <other_name>Riastap</other_name>
    <other_name>Haemocomplettan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females

          -  Age 18 years and above

          -  Patients eligible for a first-time coronary artery bypass(CABG) surgery with a
             preoperative fibrinogen plasma concentration under 3,8 g/L

          -  Signed informed consent to participate in the study

        Exclusion Criteria:

          -  Patients undergoing redo surgery

          -  Clinical or laboratory signs of bleeding disorder

          -  Clinical or laboratory signs of significant liver disease, or,other significant
             disease or condition which in the investigators judgment interfere with hemostasis

          -  Any medications with agents which may interfere with hemostasis within 14 days prior
             to study start. Clopidogrel and warfarin are withdrawn at least 24 hours before
             surgery. Oral aspirin is allowed co-medication.

          -  Administration of other investigational drugs within eight weeks preceding the
             preentry examination

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Jeppsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiothoracic Surgery unit, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2009</study_first_submitted>
  <study_first_submitted_qc>August 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2009</study_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Anders Jeppssons</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Fibrinogen</keyword>
  <keyword>Postoperative bleeding</keyword>
  <keyword>Transfusions</keyword>
  <keyword>CABG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

